Prediction: Pfizer Will Beat the Market Over the Next 5 Years

Pfizer's financial results have been subpar in recent years. The company's newer products are starting to come into their own. The drugmaker's pipeline could lead to even more important brand-new ...
AOL

Pfizer Could Hit $36 by Year-End as Analysts See 2-to-1 Payoff on Key Prostate Cancer Trial

Tue, March 24, 2026 at 2:52 PM UTC Pfizer (NYSE:PFE) has quietly built momentum in 2026, with shares up 6.61% year-to-date and 2.70% over the past year. The stock is currently trading near $26.84 but ...

Guggenheim Reaffirms Buy on Pfizer (PFE) Ahead of Pipeline Catalysts

Pfizer Inc. (NYSE:PFE) ranks among the best low-risk investments in May 2026. On April 13, Guggenheim reaffirmed a Buy rating and a $36 price target for Pfizer Inc. (NYSE:PFE) as the firm revised its ...
Hosted on MSN

Guggenheim Maintains Pfizer (PFE) Buy Recommendation

Fintel reports that on November 24, 2025, Guggenheim maintained coverage of Pfizer (NYSE:PFE) with a Buy recommendation. Analyst Price Forecast Suggests 17.56% Upside As of November 17, 2025, the ...

Pfizer Inc.

View Pfizer Inc. PFE stock quote prices, financial information, real-time forecasts, and company news from CNN.